Aspirin shows superior antiplatelet potency over beraprost, sarpogrelate
MedWire News: Aspirin has superior antiplatelet activity when its ability to prevent in vitro occlusion was compared with that of beraprost and sarpogrelate, a study among healthy volunteers in Korea has shown.
Soon Bae Kim (Asan Medical Center, Seoul) and colleagues explain that the recent introduction of the platelet function analyzer 100 (PFA-100), a device that reports platelet closure time, has made it more convenient for physicians to study platelet function in response to antiplatelet agents.
In the present study, Kim and team compared the antiplatelet potency of sarpogrelate, aspirin, and beraprost in 20 healthy volunteers according to in vitro closure time measured by the PFA-100 with collagen/epinephrine (CEPI).
Volunteers were assigned to receive sarpogrelate (300 mg daily), aspirin (100 mg daily), or beraprost (120 µg daily) for 14 days, followed by 14 days of washout, and then switched to another of the medications for 14 days. All volunteers repeated the course until they had received all three drugs.
The researchers report that there was no difference in CEPI-closure time between baseline and day 14 among patients who received sarpogrelate.
In contrast, aspirin significantly prolonged the CEPI-closure time from 145 seconds at baseline to 259 seconds on day 14, while beraprost prolonged the CEPI-closure time from 134 to 150 seconds. Of note, the CEPI-closure time change was significantly greater for aspirin than for beraprost, at 178% versus 112%, respectively.
The researchers also measured bleeding time, von Willebrand factor, D-dimer, high sensitivity C-reactive protein, and fibrinogen but found that none of the drugs changed the bleeding times or levels of each of these parameters.
“Ingestion of aspirin and beraprost for 14 days significantly prolonged in vitro closure time but ingestion of sarpogrelate for 14 days did not,” write Kim and co-authors in the journal Blood, Coagulation and Fibrinolysis.
They conclude: “Aspirin was superior to beraprost in antiplatelet potency, as assessed by in vitro closure time with CEPI.
“This study could be a basis for further studies with symptomatic patients using the PFA-100.”
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
By Laura Dean